These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2053115)

  • 21. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients.
    Stangier J; Su CA; Roth W
    J Int Med Res; 2000; 28(4):149-67. PubMed ID: 11014323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemorheologic effects of vasodilation in essential hypertension.
    Wysocki M; Andersson OK; Persson B; Bagge U; Braide M
    Angiology; 1996 Sep; 47(9):869-78. PubMed ID: 8810653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacokinetics of irbesartan in hypertensive children and adolescents.
    Sakarcan A; Tenney F; Wilson JT; Stewart JJ; Adcock KG; Wells TG; Vachharajani NN; Hadjilambris OW; Slugg P; Ford NF; Marino MR
    J Clin Pharmacol; 2001 Jul; 41(7):742-9. PubMed ID: 11452706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
    Hübner R; Högemann AM; Sunzel M; Riddell JG
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cadralazine for the treatment of preeclampsia. An open, noncomparative, dose-finding pilot study.
    Voto LS; Lapidus AM; Catuzzi P; Uranga Imaz F; Zin C; Margulies M
    Hypertension; 1992 Feb; 19(2 Suppl):II132-6. PubMed ID: 1735567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of cadralazine in human plasma and urine by high-performance liquid chromatography.
    Hauffe SA; Dubois JP
    J Chromatogr; 1984 May; 290():223-30. PubMed ID: 6736162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetics of amlodipine in hypertensive children and adolescents.
    Flynn JT; Nahata MC; Mahan JD; Portman RJ;
    J Clin Pharmacol; 2006 Aug; 46(8):905-16. PubMed ID: 16855075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological studies on cadralazine: a new antihypertensive vasodilator drug.
    Semeraro C; Dorigotti L; Banfi S; Carpi C
    J Cardiovasc Pharmacol; 1981; 3(3):455-67. PubMed ID: 6168827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disposition and pharmacokinetics of cadralazine and individual metabolites in man.
    Schütz H; Faigle JW; Küng W; Theobald W
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):147-53. PubMed ID: 4043143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pharmacology and pharmacokinetics of prizidilol in hypertensive patients.
    Chaignon M; Decourt S; Guelpa G; Rocher I; Flouvat B; Guédon J
    J Cardiovasc Pharmacol; 1983; 5(6):1068-73. PubMed ID: 6196556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemodynamic profile of the antihypertensive vasodilator cadralazine in conscious dogs.
    Dorigotti L; Ferni G; Lombroso M; Semeraro C
    Arzneimittelforschung; 1984; 34(9):984-7. PubMed ID: 6542375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Influence of acetylation phenotype on the pharmacokinetics and pharmacodynamics data of cadralazine in normotensive subjects].
    Brunel P; Lecaillon JB; Imhof P; Menard J
    Arch Mal Coeur Vaiss; 1989 Jul; 82(7):1257-60. PubMed ID: 2510657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of rilmenidine in patients with chronic renal insufficiency and in hemodialysis patients.
    Aparicio M; Dratwa M; el Esper N; Fillastre JP; Levaltier B; Lins R; Meyrier A; Mignon F; Ryckelynck JP; Sennesael J
    Am J Cardiol; 1994 Dec; 74(13):43A-50A. PubMed ID: 7998585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency.
    Gehr TW; Tenero DM; Boyle DA; Qian Y; Sica DA; Shusterman NH
    Eur J Clin Pharmacol; 1999 Jun; 55(4):269-77. PubMed ID: 10424319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clevidipine: a review of its use in the management of acute hypertension.
    Deeks ED; Keating GM; Keam SJ
    Am J Cardiovasc Drugs; 2009; 9(2):117-34. PubMed ID: 19331440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the antihypertensive activity of cadralazine (ISF 2469) and dihydralazine during chronic treatment.
    Strocchi E; Costa FV; Caldari R; Malini PL; Marata AM; Parini J; Ambrosioni E
    Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):519-23. PubMed ID: 6642790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cadralazine challenge in patients with previous hydralazine-induced lupus: a 6-month study.
    Pålsson L; Weiner L; Englund G; Henning M
    Clin Pharmacol Ther; 1989 Aug; 46(2):177-81. PubMed ID: 2758727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus.
    Zhao C; Vaidyanathan S; Yeh CM; Maboudian M; Armin Dieterich H
    Clin Pharmacokinet; 2006; 45(11):1125-34. PubMed ID: 17048976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Felodipine pharmacokinetics and plasma concentration vs effect relationships.
    Blychert E
    Blood Press Suppl; 1992; 2():1-30. PubMed ID: 1343111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Open pilot study of the activity and tolerability of cadralazine in hypertensive patients resistant to other therapy].
    Angelino PF; Bensoni M; Gastaldo D; Minelli M; Parini M; Lavezzaro GC
    Minerva Cardioangiol; 1982 Mar; 30(3):69-74. PubMed ID: 7088296
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.